Aubrey N Michi1,2, Bryan G Yipp2,3, Antoine Dufour1,4, Fernando Lopes5,6, David Proud7,8. 1. Department of Physiology and Pharmacology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada. 2. Snyder Institute for Chronic Diseases, University of Calgary, Calgary, AB, Canada. 3. Department of Critical Care Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada. 4. McCaig Institute for Bone and Joint Health, University of Calgary, Calgary, AB, Canada. 5. Institute of Parasitology, McGill University, Ste-Anne-de-Bellevue, QC, Canada. 6. Department of Microbiology and Immunology, McGill University, Montreal, QC, Canada. 7. Department of Physiology and Pharmacology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada. dproud@ucalgary.ca. 8. Snyder Institute for Chronic Diseases, University of Calgary, Calgary, AB, Canada. dproud@ucalgary.ca.
Abstract
Human rhinoviruses (HRV) are common cold viruses associated with exacerbations of lower airways diseases. Although viral induced epithelial damage mediates inflammation, the molecular mechanisms responsible for airway epithelial damage and dysfunction remain undefined. Using experimental HRV infection studies in highly differentiated human bronchial epithelial cells grown at air-liquid interface (ALI), we examine the links between viral host defense, cellular metabolism, and epithelial barrier function. We observe that early HRV-C15 infection induces a transitory barrier-protective metabolic state characterized by glycolysis that ultimately becomes exhausted as the infection progresses and leads to cellular damage. Pharmacological promotion of glycolysis induces ROS-dependent upregulation of the mitochondrial metabolic regulator, peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α), thereby restoring epithelial barrier function, improving viral defense, and attenuating disease pathology. Therefore, PGC-1α regulates a metabolic pathway essential to host defense that can be therapeutically targeted to rescue airway epithelial barrier dysfunction and potentially prevent severe respiratory complications or secondary bacterial infections.
Human rhinoviruses (HRV) are common cold viruses associated with exacerbations of lower airways diseases. Although viral induced pan class="Disease">epithelial damage mediates inflammation, the molecular mechanisms responsible for airway epithelial damage and dysfunction remain undefined. Using experimental HRV infection studies in highly differentiated human bronchial epithelial cells grown at air-liquid interface (ALI), we examine the links between viral host defense, cellular metabolism, and epithelial barrier function. We observe that early HRV-C15 infection induces a transitory barrier-protective metabolic state characterized by glycolysis that ultimately becomes exhausted as the infection progresses and leads to cellular damage. Pharmacological promotion of glycolysis induces ROS-dependent upregulation of the mitochondrial metabolic regulator, peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α), thereby restoring epithelial barrier function, improving viral defense, and attenuating disease pathology. Therefore, PGC-1α regulates a metabolic pathway essential to host defense that can be therapeutically targeted to rescue airway epithelial barrier dysfunction and potentially prevent severe respiratory complications or secondary bacterial infections.
Authors: William G Flight; Rowland J Bright-Thomas; Peter Tilston; Kenneth J Mutton; Malcolm Guiver; Julie Morris; A Kevin Webb; Andrew M Jones Journal: Thorax Date: 2013-10-14 Impact factor: 9.139
Authors: Yury A Bochkov; Kelly Watters; Shamaila Ashraf; Theodor F Griggs; Mark K Devries; Daniel J Jackson; Ann C Palmenberg; James E Gern Journal: Proc Natl Acad Sci U S A Date: 2015-04-06 Impact factor: 11.205
Authors: T Seemungal; R Harper-Owen; A Bhowmik; I Moric; G Sanderson; S Message; P Maccallum; T W Meade; D J Jeffries; S L Johnston; J A Wedzicha Journal: Am J Respir Crit Care Med Date: 2001-11-01 Impact factor: 21.405
Authors: Jason C L Spurrell; Shahina Wiehler; Raza S Zaheer; Scherer P Sanders; David Proud Journal: Am J Physiol Lung Cell Mol Physiol Date: 2005-03-11 Impact factor: 5.464
Authors: M Terajima; M Yamaya; K Sekizawa; S Okinaga; T Suzuki; N Yamada; K Nakayama; T Ohrui; T Oshima; Y Numazaki; H Sasaki Journal: Am J Physiol Date: 1997-10
Authors: Jonathan M Corne; Clare Marshall; Sandra Smith; Jacquie Schreiber; Gwendolyn Sanderson; Stephen T Holgate; Sebastian L Johnston Journal: Lancet Date: 2002-03-09 Impact factor: 79.321
Authors: David Proud; Ronald B Turner; Birgit Winther; Shahina Wiehler; Jay P Tiesman; Tim D Reichling; Kenton D Juhlin; Andy W Fulmer; Begonia Y Ho; Amy A Walanski; Cathy L Poore; Haruko Mizoguchi; Lynn Jump; Marsha L Moore; Claudine K Zukowski; Jeffrey W Clymer Journal: Am J Respir Crit Care Med Date: 2008-07-24 Impact factor: 21.405
Authors: Mahyar Aghapour; Christy B M Tulen; Mohsen Abdi Sarabi; Sönke Weinert; Mathias Müsken; Borna Relja; Frederik-Jan van Schooten; Andreas Jeron; Rüdiger Braun-Dullaeus; Alexander H Remels; Dunja Bruder Journal: Cells Date: 2022-05-28 Impact factor: 7.666
Authors: Talita B Gagliardi; Monty E Goldstein; Daniel Song; Kelsey M Gray; Jae W Jung; Maxinne A Ignacio; Kimberly M Stroka; Gregg A Duncan; Margaret A Scull Journal: PLoS Pathog Date: 2022-01-07 Impact factor: 6.823
Authors: Adrian Endres; Christian Hügel; Helena Boland; Michael Hogardt; Ralf Schubert; Danny Jonigk; Peter Braubach; Gernot Rohde; Carla Bellinghausen Journal: Front Cell Infect Microbiol Date: 2022-02-21 Impact factor: 5.293
Authors: Erwan Sallard; Katarzyna Niespodziana; Maja Bajic; Thomas Schlederer; Peter Errhalt; Ann-Kathrin Behrendt; Stefan Wirth; Almut Meyer-Bahlburg; Anja Ehrhardt; Rudolf Valenta; Malik Aydin Journal: Viruses Date: 2022-08-24 Impact factor: 5.818